Igor Kuric

Dr. Igor Kuric

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
STSvetlana Tomic
Svetlana Tomic
IKIgor Kuric
Igor Kuric
TKTihana Gilman Kuric
Tihana Gilman Kuric
ZPZvonimir Popovic
Zvonimir Popovic
JKJagoda Kragujevic
Jagoda Kragujevic
SMSara Matoša
Sara Matoša
Tomic S, et al. J Clin Neurol. 2022 Nov;18(6):628-634. https://doi.org/10.3988/jcn.2022.18.6.628

25 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TKTihana Gilman Kuric
Tihana Gilman Kuric
ZPZvonimir Popovic
Zvonimir Popovic
SMSara Matosa
Sara Matosa
Aleksander SadikovAleksander Sadikov
Aleksander Sadikov
Vida GroznikVida Groznik
Vida Groznik
STSvetlana Tomic
Svetlana Tomic
Background/Objectives: Cervical dystonia (CD) is a condition characterized by involuntary activity of cervical muscles, which is often accompanied by various non-motor symptoms. Recent studies indicate impaired saccadic eye movements in CD. Local administration of botulinum toxin type A (BoNT/A), which causes temporary paralysis of the injected muscle, is the first-line treatment of focal dystonia, including CD. To our knowledge, concurrent observation of the effect of BoNT/A on smooth eye movements, voluntary saccades, memory-guided saccades, and antisaccades in CD has not yet been explored. The aim of this study was to assess the effect of BoNT/A on eye movements and non-motor symptoms in patients with CD, which, when altered, could imply a central effect of BoNT/A. Methods: Thirty patients with CD performed smooth pursuit, prosaccadic expression, memory-guided saccades, and antisaccade tasks; eye movements were recorded by an eye tracker. Motor and non-motor symptoms, including depression, anxiety, pain, disability, and cognitive changes prior to and after BoNT/A administration, were also evaluated. Results: The number of correct onward counts (p < 0.001), overall correct memory-guided saccades count (p = 0.005), motor symptoms (p = 0.001), and non-motor symptoms, i.e., anxiety (p = 0.04), depression (p = 0.02), and cognition (p < 0.001) markedly improved after BoNT/A administration. Conclusions: Memory-guided saccades, depression, and anxiety improve after BoNT/A in CD.